MedTrace Logo

A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants

NCT06088784 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-12-19

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or disease-modifying treatments for Parkinson Disease.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ATH-399A

Orally administered drug in capsule form.

DRUG

Placebo

Orally administered drug in capsule form.

DRUG

ATH-399A 10 mg

Participants will receive single oral dose of 10 mg of ATH-399A capsule

DRUG

5 mg ATH-399A capsule

Participants will receive single oral dose of 5mg of ATH-399A capsule

DRUG

20mg ATH-399A capsule

Participants will receive single oral dose of 20mg of ATH-399A capsule

DRUG

40mg ATH-399A capsule

Participants will receive single oral dose of 40mg of ATH-399A capsule

DRUG

80mg ATH-399A capsule

Participants will receive single oral dose of 80mg of ATH-399A capsule

Sponsors & Collaborators

  • NurrOn Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • HanAll BioPharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-19
Primary Completion
2024-04-24
Completion
2024-04-24

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06088784 on ClinicalTrials.gov